jRCT2080222487未知3 期
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Tadalafil for Duchenne Muscular Dystrophy
适应症
试验速览
- 阶段
- 3 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 7age old over 至 14age old under（—）
- 性别
- Male
入选标准
- •Males with proven DMD
- •Ages 7-14 years inclusive
- •Able to complete the six minute walk distance (6MWD) test with results within 20% of each other at a minimum of 2 pre-randomization assessments
排除标准
- 未提供
研究者
相似试验
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients with Hereditary Angioedema Type I or IIHereditary AngioedemajRCT2051220178KalVista Pharmaceuticals, Ltd.12
进行中（未招募）
不适用
A Phase 3 Study in Moderate to Severe Rheumatoid ArthritisModerately to severely active rheumatoid arthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-002339-27-BEEli Lilly and Company660
进行中（未招募）
1 期
A Phase 3 Study in Moderate to Severe Rheumatoid ArthritisModerately to severely active rheumatoid arthritisMedDRA version: 16.1 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-002339-27-GBEli Lilly and Company684
进行中（未招募）
1 期
A study to evaluate if different doses of KVD900 are safe and effective in treating attacks in patients with Hereditary Angioedema.EUCTR2021-001226-21-NLKalVista Pharmaceuticals Ltd114
进行中（未招募）
1 期
A Phase 3 study of investigational drug ISIS 678354 administered under skin to patients with severely increased amount of triglycerides in blood.Severe hypertryglyceridemiaMedDRA version: 20.0Level: PTClassification code 10059183Term: Familial hypertriglyceridaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10020607Term: HyperchylomicronemiaSystem Organ Class: 100000004861EUCTR2021-002192-19-PTIonis Pharmaceuticals, Inc.540